Immunome Inc
IMNM
Market Cap$762.23M
Close$
$2.47
72.9% downside
Current Fair Value
72.9% downsideOvervalued by 72.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $762.23 Million |
|---|---|
| Enterprise Value | $522.53 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5 |
| Beta | 2.01 |
| Outstanding Shares | 79,410,354 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.39 |
|---|---|
| PEG | 5 |
| Price to Sales | - |
| Price to Book Ratio | 3.04 |
| Enterprise Value to Revenue | 47.77 |
| Enterprise Value to EBIT | -2.74 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...